SI-BONE, Inc. (SIBN) shares climbed 8.47% in pre-market trading on Tuesday after the medical device company reported record fourth quarter revenues and achieved profitability for the first time.

The company, which develops products to treat musculoskeletal disorders of the sacropelvic anatomy, saw its stock soar following the strong financial results. SI-BONE delivered worldwide revenue of $49 million in Q4, up 26% year-over-year, driven by robust demand for its innovative product portfolio targeting conditions like sacroiliac joint dysfunction, adult deformity, and pelvic fractures.

Most notably, SI-BONE achieved positive adjusted EBITDA of $1.9 million in Q4, marking a significant milestone as it progresses towards its goal of generating positive free cash flow. For full year 2024, the company's adjusted EBITDA loss narrowed by over 70% to $5.1 million, highlighting the scalability of its business model.

SI-BONE attributed its strong performance to the successful launches of new products like Granite 9.5 and TNT, which exceeded adoption expectations and drove increased physician engagement across multiple procedure types. The company also saw continued momentum in its core SI joint fusion business, bolstered by growing demand from interventional spine physicians.

Looking ahead, SI-BONE expects to sustain its growth trajectory, guiding for full-year 2025 worldwide revenue of $193.5 million to $195.5 million, representing year-over-year growth of approximately 16% to 17%. The company anticipates achieving positive adjusted EBITDA for the full year 2025 as it leverages its expanding profitability and asset-light business model.